Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Martino
R
R
Bretagne
S
S
Rovira
M
M
Ullmann
A J
AJ
Maertens
J
J
Held
T
T
Deconinck
E
E
Cordonnier
C
C
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D001782:Blood Donors; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control / Q000635:transmission; D011292:Premedication; D016036:Seroepidemiologic Studies; D014122:Toxoplasma / Q000276:immunology / Q000502:physiology; D014123:Toxoplasmosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control / Q000635:transmission; D014184:Transplantation, Homologous / Q000009:adverse effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000913:Antibodies, Protozoan; D015662:Trimethoprim, Sulfamethoxazole Drug Combination